EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Large‐scale meta‐analysis of infection risk with JAK – STAT inhibitors in 29,000 patients

Máté Krebs iD, Lili Gulyás, Karen Krisztina Fazekas, Benedek Nagy, Mária Veronika Kolonics, Fanni Adél Meznerics, Norbert Kiss, András Bánvölgyi, Péter Hegyi, Péter Holló, Lajos Vince Kemény

Journal of the European Academy of Dermatology and Venereology · 2026-10 · 40 (10) · 1662-1674

DOI: 10.1111/jdv.70508 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 26.05.2026. Verfasst von Máté Krebs und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Janus Kinases, STAT Transcription Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Janus kinase signal transducer and transcription activator (JAK–STAT) inhibitors have revolutionized the treatment of immune‐mediated inflammatory diseases (IMIDs) of the skin, such as in atopic dermatitis, alopecia areata and vitiligo. Although several meta‐analyses have confirmed their efficacy, concerns remain about the risk of infection, as the JAK–STAT pathway plays a key role in immune defence. Previous meta‐analyses examined only selected, pre‐specified infection categories and have not comprehensively evaluated all reported infection types or compared systemic and topical agents.

Methods

We performed a systematic review and meta‐analysis of randomized controlled trials (RCTs) that reported infection‐related adverse events in patients treated with systemic or topical JAK–STAT inhibitors for IMIDs of the skin. The study followed the PRISMA 2020 and Cochrane guidelines (PROSPERO: CRD 42024615839). Overall risk ratios (RRs) with 95% confidence intervals (CI) were calculated using a random‐effects model.

Results

Seventy‐four RCTs were included, involving more than 29,000 patients. JAK–STAT inhibitors were associated with an increased risk of influenza (RR = 2.12, 95% CI 1.03–4.36), bronchitis (RR = 2.03, 95% CI 1.43–2.88) and herpes zoster (RR = 1.67, 95% CI 1.29–2.15) compared to a placebo. The risk was particularly elevated in patients with atopic dermatitis (influenza: 3.22, 95% CI 2.03–5.10, herpes zoster: RR = 2.00, 95% CI 1.34–2.99). No significant risks were identified for serious, fungal or opportunistic infections, and topical JAK–STAT inhibitors demonstrated a favourable safety profile comparable to vehicle controls.

Conclusions

This meta‐analysis provides a comprehensive assessment of the risk of infection associated with JAK–STAT inhibitors in IMIDs of the skin. Although overall safety is acceptable, clinicians should be aware of the higher infection risk of influenza and herpes zoster and should consider vaccination and preventive strategies for high‐risk patients with atopic dermatitis. The main limitation is that the included studies involved highly selected populations with few comorbidities and short follow‐up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsJanus KinasesSTAT Transcription FactorsHumansRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

JAK–STAT inhibitorJanus kinase inhibitorsabrocitinibadverse reactionsatopic dermatitisbaricitinibbrepocitinibdelgocitinibdeucravacitinibdeuruxolitinibfilgotinibgusacitinibherpes zosterimmune‐mediated inflammatory diseases of the skininfection risk

Substanzen

Janus Kinase InhibitorsJanus KinasesSTAT Transcription Factors

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
  • Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
  • Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
  • Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary.
  • HCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
  • Department of Physiology, Semmelweis University, Budapest, Hungary.

ORCID-Profile: Máté Krebs

Zitieren

APA

Krebs, M., Gulyás, L., Fazekas, K. K., Nagy, B., Kolonics, M. V., Meznerics, F. A., Kiss, N., Bánvölgyi, A., Hegyi, P., Holló, P., & Kemény, L. V. (2026). Large‐scale meta‐analysis of infection risk with JAK – STAT inhibitors in 29,000 patients. Journal of the European Academy of Dermatology and Venereology, 40(10), 1662-1674. https://doi.org/10.1111/jdv.70508

Vancouver

Krebs M, Gulyás L, Fazekas KK, Nagy B, Kolonics MV, Meznerics FA, et al. Large‐scale meta‐analysis of infection risk with JAK – STAT inhibitors in 29,000 patients. Journal of the European Academy of Dermatology and Venereology. 2026;40(10):1662-1674. doi:10.1111/jdv.70508

BibTeX
@article{Krebs2026,
  author = {Krebs, Máté and Gulyás, Lili and Fazekas, Karen Krisztina and Nagy, Benedek and Kolonics, Mária Veronika and Meznerics, Fanni Adél and Kiss, Norbert and Bánvölgyi, András and Hegyi, Péter and Holló, Péter and Kemény, Lajos Vince},
  title = {Large‐scale meta‐analysis of infection risk with JAK – STAT inhibitors in 29,000 patients},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {10},
  pages = {1662--1674},
  doi = {10.1111/jdv.70508}
}
Kostenlos starten →